Skip to content

The role of transcutaneous vagus nerve stimulation in post-error slowing

The role of transcutaneous vagus nerve stimulation in post-error slowing - transcutaneous vagal nerve stimulation and post-error slowing

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON41900
Enrollment
48
Registered
2014-10-20
Start date
2015-01-12
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

het onderzoek is van algemeen cognitief-psychologische aard en heeft geen betrekking op stoornissen of aandoeningen. not applicable

Interventions

tVNS NEUROSTIMULATING DEVICE A tVNS instrument consisting of two titan electrodes mounted on a gel frame and connected to a wired neurostimulating device (CM02, Cerbomed, Erlangen, Germany) will be

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy adult participants, aged 18-30 years. For safety reasons (i.e. to ensure optimal communication between participants and experimenter), only native Dutch speakers will be included as participants

Exclusion criteria

Exclusion criteria: Exclusion criteria are: epilepsy, bradycardia, cardiac arrhythmia, cardiac diseases, head trauma, pregnancy, alcoholism, migraine and medication or drug use, neurological or psychiatric disorders, metal pieces in the body.

Design outcomes

Primary

MeasureTime frame
The main study parameters are cognitive task performance as reflected by reaction times and error rates, in addition to pupillary response measurements. The endpoints are the modulatory effects of active tVNS stimulation relative to sham stimulation on the main study parameters.

Secondary

MeasureTime frame
Secondary study parameters are individual differences as operationalised by participants* scores on personality/mood questionnaires. The endpoints are correlations and statistical analyses with the results from the questionnaire scores.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)